Clinical trials located in

Liberec

Liberec city is located in Czechia. Currently, 7 clinical trials are being conducted in this city.

Liberec, nestled in the Czech Republic, is a city of rich history and cultural heritage. Founded in the 14th century, it boasts the Ještěd Tower, an iconic TV tower and hotel, shaped like a hyperboloid and perched atop Ještěd Mountain. The city is also home to the North Bohemian Museum, one of the oldest in the Czech Republic, and the Liberec Zoo, the first in the country. The Town Hall, an exquisite example of Neo-Renaissance architecture, underscores Liberec’s architectural diversity. Surrounded by the Jizera Mountains, Liberec serves as a hub for winter sports enthusiasts.

  • CT-EU-00038484

    Evaluating efinopegdutide treatment for nonalcoholic steatohepatitis

    This clinical trial explores a new treatment for non-alcoholic steatohepatitis (NASH), a liver condition. It tests the safety and effectiveness of efinopegdutide, a medication administered through weekly injections. Participants, diagnosed with NASH but not severe liver damage, will receive either the medication or a placebo. The study aims to improve liver health and assess potential side effects. It prioritizes participant safety and involves regular health monitoring.

    • Efinopegdutide
    • Semaglutide
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Radium-223 radiation vs. new hormone therapy in prostate cancer trial

    In this study, scientists are looking into two treatments for prostate cancer that has spread to the bone. One is a medicine called Radium-223 Dichloride or simply Xofigo which uses radiation to destroy cancer cells. The other is a new kind of treatment that stops hormones from working, as these hormones can sometimes help cancer grow. This new treatment is called Novel Anti-hormonal Therapy or NAH for short. The aim is to see which works better and to compare their safety profiles. Xofigo works by emitting a special type of radiation once it is injected into the body and absorbed by the bones. This radiation travels only a short distance, so it doesn’t harm healthy cells while killing cancerous ones. NAH, on the other hand, includes medications like abiraterone acetate (Zytiga) or enzalutamide (Xtandi) which are usually given to advanced prostate cancer patients. People taking part in this study will either receive Xofigo or NAH. Xofigo is given via an injection into a vein every 4 weeks for up to 6 months, while an oral form of NAH will be given daily until the disease progresses. Participants will be in this study for around 2 years, visiting the hospital or clinic every 2 weeks initially and then less often. There will be blood and urine tests and questionnaires about well-being and pain management.

    • Radium-223 dichloride/BAY88-8223
    • enzalutamide
    • prednisolone
    • abiraterone acetate
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Czechia:

.